AufrichtC., EndemannM., BidmonB., ArbeiterK., MuellerT., RegeleH.Peritoneal dialysis fluids induce the stress response in human mesothelial cells.Perit Dial Int2001; 21: 85–8.
2.
WieslanderA.P., KjellstrandP.T., RippeB.Heat sterilization of glucose-containing fluids for peritoneal dialysis: Biological consequences of chemical alterations.Perit Dial Int1995; 15(7 Suppl): S52–9.
3.
WitowskiJ., TopleyN., JörresA., LiberekT., ColesG.A., WilliamsJ.D.Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis.Kidney Int1995; 47: 282–93.
WitowskiJ., WisniewskaJ., KorybalskaK., BenderT.O., BreborowiczA., GahlG.M.Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells.J Am Soc Nephrol2001; 12: 2434–41.
FusshoellerA., PlailM., GrabenseeB., PlumJ.Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: A prospective, randomized study.Nephrol Dial Transplant2004; 19: 2101–6.
8.
RippeB., SimonsenO., HeimburgerO., ChristenssonA., HaraldssonB., StelinG.Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Kidney Int2001; 59: 348–57.
9.
ZeierM., SchwengerV., DeppischR., HaugU., WeigelK., BahnerU.Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation?Kidney Int2003; 63: 298–305.
10.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
11.
HaasS., SchmittC.P., ArbeiterK., BonzelK.E., FischbachM., JohnU.Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis.J Am Soc Nephrol2003; 14: 2632–8.
12.
KredietR.T.Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.Perit Dial Int2001; 21: 560–7.
13.
WitowskiJ., KorybalskaK., KsiazekK., Wisniewska-ElnurJ., JörresA., LageC.Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.Nephrol Dial Transplant2004; 19: 917–24.
14.
HoriuchiT., MiyamotoK., MiyamotoS., FujitaM., SanoN., MinamiyamaK.Image analysis of remesothelialization following chemical wounding of cultured human peritoneal mesothelial cells: The role of hyaluronan synthesis.Kidney Int2003; 64: 2280–90.
15.
Wieczorowska-TobisK., BrelinskaR., WitowskiJ., Passlick-DeetjenJ., SchaubT.P., SchillingH.Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products.Perit Dial Int2004; 24: 48–57.
16.
TauerA., KnerrT., NiwaT., SchaubT.P., LageC., Passlick-DeetjenJ.In vitro formation of N(epsilon)-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis.Biochem Biophys Res Commun2001; 280: 1408–14.
17.
MortierS., FaictD., SchalkwijkC.G., LameireN.H., De VrieseA.S.Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.Kidney Int2004; 66: 1257–65.
18.
ParkS.H., LeeE.G., KimI.S., KimY.J., ChoD.K., KimY.L.Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.Perit Dial Int2004; 24: 115–22.
19.
InagiR., MiyataT., YamamotoT., SuzukiD., UrakamiK., SaitoA.Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis.FEBS Lett1999; 463: 260–4.
20.
Mandl-WeberS., CohenC.D., HaslingerB., KretzlerM., SitterT.Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells.Kidney Int2002; 61: 570–8.
21.
MusiB., BraideM., CarlssonO., WieslanderA., AlbrektssonA., KettelerM.Biocompatibility of peritoneal dialysis fluids: Long-term exposure of nonuremic rats.Perit Dial Int2004; 24: 37–47.
22.
MiyataT., HorieK., UedaY., FujitaY., IzuharaY., HiranoH.Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds.Kidney Int2000; 58: 425–35.
23.
van deK.J., SchalkwijkC.G., KoningsC.J., CheriexE.C., van der SandeF.M., SchefferP.G.N(epsilon)-(carboxymethyl)lysine, N(epsilon)-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function: A study in peritoneal dialysis patients.Nephrol Dial Transplant2004; 19: 910–16.
